Document Type : Original Article(s)
Authors
1 Surgical Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
2 Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
3 Clinical Oncology Department, Assiut University Hospital, Assiut University, Assiut, Egypt
Abstract
Background: In the present research, we aimed to estimate the effect of the number of resected lymph nodes (LN) on the survival outcomes of patients with resectable gastric cancer; we investigated whether 16 LNs remained the optimal threshold and whether a specific subset of patients could benefit from further LN dissected.
Method: This cohort study included consecutive patients who underwent surgical resection for gastric cancers from the start of 2012 to the end of 2014. Demographic, clinic-pathologic, laboratory data (including complete blood picture, renal function tests, liver function tests, C-reactive protein, Prothrombin profile, and electrolytes), type of surgery, systemic chemotherapy, treatment, and survival data were retrospectively collected from the patients' files.
Results: The mean overall survival ± standard error (SE) was 23.051 ± 2.249 months with 95% confidence interval (CI) = 18.644-27.459, while the mean disease-free survival ± SE was 20.675 ± 2.414 months with 95% CI = 15.944-25.906. D2 dissection was associated with significantly better OS and disease-free survival (P = 0.001 and P = 0.001, respectively). The mean OS for the patients with <16 lymph node dissected was 13.480 ± 1.468 with 95% CI = 10.603-16.357; whereas for those patients with <16 lymph nodes dissected, it was 20.738 ± 2.065 with 95% CI = 16.690-24.786 months, log-rank = 8.030 (P = 0.005).
Conclusion: The benefit of D2 lymphadenectomy, and subsequently dissecting more LNs, still remains under question; however, if morbidity and mortality are kept at a minimum level, D2 dissection could be advantageous. Our study concluded that harvesting further LNs was associated with more survival benefit.
Keywords
The abstract was published previously in Annals of Oncology, Volume 31, Supplement 3, S127, July 01, 2020: https://doi.org/10.1016/j.annonc.2020.04.198
How to cite this article:
Fakhry H, Zahran AM, Rayan A. Impact of the number of harvested lymph nodes on the survival of Egyptian patients with gastric cancer: Middle eastern tertiary center experience. Middle East J Cancer. 2022;13(3):543-55. doi: 10.30476/mejc.2022.87873.1443.
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107.
- Schmidt B, Yoon SS. D1 versus D2 lymphadenectomy for gastric cancer. J Surg Oncol. 2013;107(3):259-64. doi: 10.1002/jso.23127.
- Giuliani A, Miccini M, Basso L. Extent of lymphadenectomy and perioperative therapies: two open issues in gastric cancer. World J Gastroenterol. 2014;20(14):3889-904. doi: 10.3748/wjg.v20.i14.3889.
- Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomized nationwide Dutch D1D2 trial.Lancet Oncol. 2010;11:439-49. doi: 10.1016/S1470-2045(10)70070-X.
- McCulloch P, Nita ME, Kazi H, Gama-Rodrigues J. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev. 2003;(4):CD001964. doi: 10.1002/14651858.CD001964. Update in: Cochrane Database Syst Rev. 2004;(4):CD001964.
- Marrelli D, Morgagni P, de Manzoni G, Coniglio A, Marchet A, Saragoni L, et al. Prognostic value of the 7th AJCC/UICC TNM classification of noncardia gastric cancer: analysis of a large series from specialized Western centers.Ann Surg. 2012; 255:486-91. doi: 1097/sla.0b013e3182389b1a.
- Marrelli D, Morgagni P, de Manzoni G, Marchet A, Baiocchi GL, Giacopuzzi S, et al. External validation of a score predictive of recurrence after radical surgery for non-cardia gastric cancer: Results of a follow-up study.J Am Coll Surg. 2015;221:280-90. doi.org/10.1016/j.jamcollsurg.2015.03.042.
- Jiang L, Yang KH, Chen Y, Guan QL, Zhao P, Tian JH, et al. Systematic review and meta-analysis of the effectiveness and safety of extended lymphadenectomy in patients with resectable gastric cancer.Br J Surg. 2014;101: 595-604. doi: 10.1002/bjs.9497.
- Verlato G, Giacopuzzi S, Bencivenga M, Morgagni P, De Manzoni G. Problems faced by evidence-based medicine in evaluating lymphadenectomy for gastric cancer.World J Gastroenterol. 2014;20:12883-91. doi: 10.3748/wjg.v20.i36.12883.
- Kodera Y, Kobayashi D, Tanaka C, Fujiwara M. Gastric adenocarcinoma with para-aortic lymph node metastasis: a borderline resectable cancer?Surg Today. 2015;45:1082-90. doi: 10.1007/s00595-014-1067-1.
- Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial.J Clin Oncol. 2004;22:2069-77. doi: 10.1200/JCO.2004.08.026.
- Degiuli M, Sasako M, Ponti A, Vendrame A, Tomatis M, Mazza C, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer.Br J Surg. 2014;101:23-31. doi: 10.1002/bjs.9345.
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.Int J Cancer. 2015;136:E359–E386. doi: 10.1002/ijc.29210.
- Wu ZY, Li JH, Zhan WH, He YL, Wan J. Effect of lymph node micro-metastases on prognosis of gastric carcinoma. World J Gastroenterol. 2007; 13:4122-5. doi: 10.3748/wjg.v13.i30.4122.
- Coburn NG. Lymph nodes and gastric cancer.J Surg Oncol. 2009;99:199-206. doi: 10.1002/jso.21224.
- Waddell T, Verheij M, Allum M, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO-ESS0-ESTRO clinical practice guidelines for diagnosis, treatment, and follow-up.Eur J Surg Oncol. 2014;40:584-91. doi: 10.1016/j.ejso.2013.09.020.
- National Comprehensive Cancer Network (2015). NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer version 3; 2015. Available at: http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. (Accessed on: 14 Dec 2015). doi: 10.6004/jnccn.2016.0137.
- Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14(2):113-23. doi: 10.1007/s10120-011-0042-4.
- Lee JH, Kim JG, Jung HK, Kim JH, Jeong WK, Jeon TJ, et al. Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer. 2014;14:87-104. doi: 10.5230/jgc.2014.14.2.87.
- Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: Ten-year results of the German Gastric Cancer Study.Ann Surg. 1998;228:449-61. doi: 1097/00000658-199810000-00002.
- Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma.J Clin Oncol. 2003;21:3647-50. doi: 10.1200/JCO.2003.01.240.
- Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol.2003;21:2912-9. doi: 10.1200/JCO.2003.05.062.
- Gholami S, Janson L, Worhunsky DJ, Tran TB, Squires MH III, Jin LX, et al. Number of lymph nodes removed and survival after gastric cancer resection: An analysis from the U.S. Gastric Cancer Collaborative. J Am Coll Surg. 2015; 221(2): 291-9. doi: 1016/j.jamcollsurg.2015.04.024.
- Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:437971. doi: 10.1155/2014/437971.
)